Attention is focusing on whether GC Pharma, which has 145mg of non-reimbursement, will be involved in selling Abbott products. Unlike conventional Fenofibrate 160mg tablets, the 145mg tablet market, which can be taken regardless of meals, is gradually heating up. This is because Abbott products are also about to be listed after Yuhan Corporation listed related products for the first time in July. In particular, Abbott is the original developer of Lipidil Supra, currently the No. 1 Fenofibrate, and attention is being paid to how Abbott's appearance will affect the market.

According to the industry on the 6th, Abbott received permission for "Lipidil NT" from the Ministry of Food and Drug Safety in June an